Market Place
Sourcing Support
Sanofi completes acquisition of Inhibrx, Inc.
30 May 2024 //
PRESS RELEASE
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
24 May 2024 //
PR NEWSWIRE
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
28 Feb 2024 //
PRESS RELEASE
Arecor to retain Inhibrx royalties in wake of Sanofi acquisition
24 Jan 2024 //
PRESS RELEASE
Inhibrx Announces Sale of INBRX-101 to Sanofi for value of up to $2.2B
23 Jan 2024 //
PR NEWSWIRE
Inhibrx Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
PR NEWSWIRE
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109
02 Nov 2023 //
PR NEWSWIRE
Inhibrx Announces Participation in Upcoming Scientific Conferences
18 Oct 2023 //
PR NEWSWIRE
Inhibrx Announces $200 Million Private Placement Financing
29 Aug 2023 //
PR NEWSWIRE
Inhibrx Granted Fast Track for INBRX-101 for Alpha-1 Antitrypsin Deficiency
30 May 2023 //
PR NEWSWIRE
Inhibrx Reports 1Q 2023 FYR and Recent Corporate Highlights
08 May 2023 //
PR NEWSWIRE
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD
26 Apr 2023 //
PR NEWSWIRE
Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results
06 Mar 2023 //
PR NEWSWIRE
NorthStar Medical Radioisotopes and Inhibrx Enter Collaboration
05 Jan 2023 //
CONTRACT PHARMA
Inhibrx Announces Participation in Upcoming Investor Conference
18 Nov 2022 //
PRESS RELEASE
Inhibrx Announces Updated Efficacy and Safety Data Ph1 Trial of INBRX-109
16 Nov 2022 //
PRNEWSWIRE
Inhibrx Reports Third Quarter 2022 Financial Results and Corporate Highlights
07 Nov 2022 //
PRNEWSWIRE
Inhibrx Jumps After Possibility of FDA Approval for INBRX-101
04 Oct 2022 //
TIPRANKS
Inhibrx Announces Opportunity for Approval for INBRX-101
04 Oct 2022 //
PRESS RELEASE
Inhibrx down 8% after announcing webcast for pathway for rare disease candidate
03 Oct 2022 //
SEEKINGALPHA
Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101
03 Oct 2022 //
PRNEWSWIRE
EMA Grants ODD to INBRX-109 for the Treatment of Chondrosarcoma
15 Aug 2022 //
PRNEWSWIRE
Inhibrx Reports Q2 2022 Financial Results and Recent Corporate Highlights
08 Aug 2022 //
PRNEWSWIRE
Inhibrx concludes Phase I dose escalation of solid tumour therapy
30 Jun 2022 //
PRESS RELEASE
INBRX-101 Shows Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency
16 May 2022 //
PRNEWSWIRE
Inhibrx To Host Webcast of Topline Results from the PI Trial of INBRX-101
12 May 2022 //
PRESS RELEASE
Inhibrx Reports First Quarter 2022 Financial Results
09 May 2022 //
PRESS RELEASE
Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?
03 May 2022 //
NASDAQ
Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101
25 Apr 2022 //
PRNEWSWIRE
US FDA grants orphan drug status to Inhibrx’s AATD treatment
03 Mar 2022 //
PHARMACEUTICAL-TECHNOLOGY
Inhibrx Selects Genialis ResponderID for Clinical Optimization Study, INBRX-109
28 Feb 2022 //
BUSINESSWIRE
Inhibrx announces initial results from phase 1 trial of INBRX-106 + Keytruda
06 Jan 2022 //
PHARMABIZ
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma
01 Dec 2021 //
BIOSPACE
Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences
01 Nov 2021 //
PRNEWSWIRE
Inhibrx shares rise on PhI trial results; Braglia`s Helsinn partners with Fosun
12 Oct 2021 //
ENDPTS
INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin
12 Oct 2021 //
BIOSPACE
Inhibrx To Host Webcast Presentation on Phase 1 Trial of INBRX-101 Result
11 Oct 2021 //
PRNEWSWIRE
Inhibrx Granted Fast Track Designation for INBRX-109
13 Jan 2021 //
BIOSPACE
Inhibrx Announces Ph 1 Dose Escalation Results INBRX-106,Hexavalent OX40 Agonist
05 Jan 2021 //
PRNEWSWIRE
